Description: |
In HepG2 cells, SecinH3 inhibits insulin signaling and associated gene expression. SecinH3 also markedly inhibits migration of preadipocyte 3T3-L1 cells. In the A549 cells, SecinH3 results in reduced proliferation by indirectly attenuating EGFR activation, and causes a synergistic antiproliferative effect when used in combination with gefitinib. In mice, SecinH3 increases the expression of gluconeogenic genes, reduces the expression of glycolytic, fatty acid and ketone body metabolism genes in the liver, reduces liver glycogen stores, and increases plasma insulin. In mice bearing H460 xenografts, SecinH3 significantly retards tumor growth through its antiproliferative and pro-apoptotic effect. For the detailed information of SecinH3, the solubility of SecinH3 in water, the solubility of SecinH3 in DMSO, the solubility of SecinH3 in PBS buffer, the animal experiment (test) of SecinH3, the cell expriment (test) of SecinH3, the in vivo, in vitro and clinical trial test of SecinH3, the EC50, IC50,and affinity,of SecinH3, For the detailed information of SecinH3, the solubility of SecinH3 in water, the solubility of SecinH3 in DMSO, the solubility of SecinH3 in PBS buffer, the animal experiment (test) of SecinH3, the cell expriment (test) of SecinH3, the in vivo, in vitro and clinical trial test of SecinH3, the EC50, IC50,and affinity,of SecinH3, Please contact DC Chemicals. |